Next Article in Journal
Screening and Characterization of Phenolic Compounds from Selected Unripe Fruits and Their Antioxidant Potential
Previous Article in Journal
Comparison of Antibacterial Activities of Korean Pine (Pinus densiflora) Needle Steam Distillation Extract on Escherichia coli and Staphylococcus aureus Focusing on Membrane Fluidity and Genes Involved in Membrane Lipids and Stress
Previous Article in Special Issue
Developing an Amide-Spacered Triterpenoid Rhodamine Hybrid of Nano-Molar Cytotoxicity Combined with Excellent Tumor Cell/Non-Tumor Cell Selectivity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 1
10.3390/molecules29010166
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines

by
Xiaoming Fu
,
Daniel Wenholz
,
Daniel S. H. Chan
,
David StC. Black
and
Naresh Kumar
*
School of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(1), 166; https://doi.org/10.3390/molecules29010166
Submission received: 31 October 2023 / Revised: 30 November 2023 / Accepted: 23 December 2023 / Published: 27 December 2023
(This article belongs to the Special Issue Exclusive Papers of the Editorial Board Members (EBMs): Advances in Bioorganic Chemistry)
Browse Figures
Versions Notes

Abstract

:
A synthetic pathway to a novel 4-aryl-3,4-dihydro-2H-1,4-benzoxazine scaffold was developed and a series of compounds based on the scaffold were synthesised as potential anticancer agents. The 4-aryl-substituted compounds were prepared via Buchwald–Hartwig cross-coupling between substituted bromobenzenes and various 1,4-benzoxazines, which in turn were generated from a cascade hydrogenation and reductive amination one-pot reaction. These analogues exhibited moderate to good potency against various cancer cell lines. Structure–activity relationship analysis indicated that the inclusion of hydroxyl groups on ring A and ring B was beneficial to biological activity, while having a para-amino group on ring C significantly enhanced potency. Molecule 14f displayed the most potent anticancer activity (IC50 = 7.84–16.2 µM against PC-3, NHDF, MDA-MB-231, MIA PaCa-2, and U-87 MG cancer cell lines), indicating its potential as a lead compound for further structural optimisation. All the synthesised compounds were fully characterised with NMR, HMRS, and IR. The novel benzoxazine scaffold described in this study holds promise and deserves further in-depth studies.

Graphical Abstract

1. Introduction

Cancer is one of the leading causes of death worldwide [1]. In 2019, over 1.8 million new cancer cases were diagnosed in the United States [2]. Lung, colorectal, breast, and prostate cancer are the most frequent forms of cancer which contribute to around 30% of all new diagnoses and at least 10% of cancer-related deaths [3].
Conventional approaches for modern drug development heavily rely on the discovery of active compounds against an individual biological target. However, such single-target methods are not always effective at delivering drugs against complex multifactorial diseases such as cancer [4]. To overcome this limitation, one strategy is to design multitarget drugs that are capable of simultaneously and specifically binding to multiple sites within the target system [5,6].
In an effort toward developing novel pharmacophores as anticancer agents, the synthetic cis- and trans-isoflavanols have attracted much attention [7]. Equol, a molecule possessing a benzopyran pharmacophore, displays low-nanomolar binding affinity to 5α-DHT and reduces the risk of developing prostate-associated disorders [8]. A series of 4-substituted isoflavonoids demonstrated potential pharmacological value by binding avidly to the estrogen receptor [9,10]. After iterative chemical modification, 4-substituted benzopyran compounds demonstrated a progressive increase in broad anticancer activity which was attributed to their potential role as tubulin polymerization inhibitors leading to delayed mitosis as a result [11]. These findings suggest that 4-substituted isoflavan is a promising pharmacophore with broad anticancer potential.
Benzoxazine analogues, particularly 1,4-benzoxazine systems, represent another important class of biologically active compounds with significant pharmaceutical value against various diseases, including cardiovascular disorders, neurodegeneration, inflammation, and cancer [12,13,14]. Triazole–benzoxazine hybrids also displayed promising anti-proliferative activities [15]. A 1,4-benzoxazine inhibited hypoxic tumours by downregulating hypoxia-induced genes while only exhibiting low toxicity to normoxic cells [16]. 2,3-Dihydro-1,4-benzoxazines were investigated as orally bioavailable anticancer agents via inhibition of angiogenesis [17]. Another type of 2,3-dihydro-1,4-benzoxazine possessed a dual antiangiogenic mechanism via both thrombin and integrin inhibitory activity [18]. A 1,4-benzoxazine sulphonamide was a potent agonist of retinoic acid receptor-related orphan receptor (ROR) and decreased cancer growth via increasing T-cell activity in the tumour microenvironment [19]. 1,4-Benzoxazin-3-one sulphonamides were evaluated as inhibitors of PI3Ka in several cancer cell lines [20,21]. Recently, a tyrosine-based benzoxazine was discovered to show promising anticancer activity via the inducement of breast cancer cell apoptosis [22]. These findings suggest that the 1,4-benzoxazine scaffold is biologically privileged for the development of anticancer agents.
Due to the similarity in the scaffolds of 4-substituted isoflavans and 3,4-dihydro-2H-1,4-benzoxazines, we hypothesized that novel 4-aryl substituted 1,4-benzoxazines might display improved toxicity and selectivity against cancer cell lines (Figure 1). In this paper, we designed, synthesised, and examined the in vitro biological activities of a small library of 1,4-benzoxazine derivatives. The reported synthetic path is efficient and enables various modifications so that novel analogues can be easily prepared. The structure–activity relationships (SAR) of these compounds provide guidance to the development of future lead candidates against cancer.

2. Results and Discussion

2.1. Chemical Synthesis and Characterization

The methodology for synthesising the benzoxazine scaffold was based on a previously published patent, with some modifications [23]. Notably, the original patent did not detail the incorporation of 4-aryl substitution. The reaction of 2-nitrophenol 1 and 2-bromoacetophenone 2a and 2-bromo-4′-methoxyacetopheone 2b under Williamson ether synthesis conditions provided the nitro intermediates 3a and 3b in good yield (Scheme 1). The nitro groups of 3a and 3b were reduced to amines using Pd/C (as opposed to NaH2PO2) [23], which was followed by intramolecular cyclization via the Mannich reaction to give the 1,4-benzoxazines 4a and 4b in a one-pot reaction. Finally, N-arylation was performed under modified Buchwald–Hartwig amination conditions with excess substituted bromobenzene to generate the 4-aryl-3,4-dihydro-2H-1,4-benzoxazine derivatives 5a–e in moderate yields of 23–50%.
With the synthesis methodology in hand, we set out to further explore the biological activities of benzoxazines by introducing a 7-methoxy group to the benzoxazine core as well as different substituents on the pendant aromatic ring, and to explore further the biological activities of these benzoxazines. Thus, 5-methoxy-2-nitrophenol 6 was alkylated with various 2-bromoacetophenones 2b, 7a, 7b to provide nitro compounds 8a–c in 73–90% yield (Scheme 2). The intermediates were subjected to catalytic hydrogenation and intramolecular cyclization to furnish 9a–c. Interestingly, small amounts of 2H-benzoxazines 10a and 10b were also isolated in addition to the main dihydrobenzoxazines 9a and 9c respectively. Different substitutions were introduced to the pendant 4-aryl group by reacting 9a–c with various substituted bromobenzenes under similar reaction conditions, furnishing the 4-aryl-3,4-dihydro-2H-1,4-benzoxazine compounds 11a–g in 24–82% yields. When 9a was coupled with 1-bromo-2,4-dimethoxybenzene in similar conditions, the unsaturated benzoxazine 12 was the only product of the coupling reaction and the anticipated dihydrobenzoxazine was not formed. The variation on the benzoxazine core was evidenced by the absence of the two doublets at around 4.2 ppm corresponding to the protons of methylene at C2 and one triplet at around 5.0 ppm corresponding to the chiral proton of C3. The methylene protons are diastereotopic due to the presence of an adjacent chiral proton which makes them chemically non-equivalent, thus giving rise to two different chemical shifts. The structure was further confirmed by the presence of a singlet at 6.69 ppm integrating for one proton corresponding to the olefinic proton H2 in 12.
Next, we wanted to evaluate the effect of amino substitution on the biological properties of the scaffold. Thus, various nitro benzoxazine derivatives were reduced by H2 in the presence of Pd/C in methanol to furnish the amine compounds 13a–e (Scheme 3).
In search of improved bioactivities for the novel benzoxazines, we further modified the analogues to investigate the effect of having hydroxyl groups in the structure. Various methoxyl benzoxazines were demethylated in the presence of BBr3 in dichloromethane to afford the hydroxyl derivatives 14a–g in good yields (Scheme 4).
The effect of heterocycle substitution was another direction we aimed to explore. Analogues 15a and 15b were prepared by coupling benzoxazines 9b and 9c with 3-bromoquinoline (Scheme 5). Compound 15b was further demethylated to obtain the hydroxyl compound 15c.

2.2. In Vitro Cancer Cell Proliferation Inhibitory Activities and Structure–Activity Relationship Study

To assess the cell growth inhibitory effect of the synthesised 1,4-dihydrobenzoxazine derivatives, their effects on cell proliferation were tested against MIA (PaCa-2) pancreatic cancer cells, (MDA-MB-231) breast cancer cells, and (PC-3) prostate cancer cells using an in vitro CellTiter-Glo assay (Table 1). Out of the 29 synthesised molecules, 11a, 13c, 13d, 14a, 14b, 14c, 14d, 14f, and 15c showed >50% activity against MIA PaCa-2 at 25 µM. Compounds 5c, 5e, 11a, and 14c displayed >40% growth inhibition against MDA-MB-231. For PC-3 cell line, compounds 13c, 13d, 14a, 14f displayed >25% activity while 14a and 14f displayed activity against both MDA-MB-231 and PC-3 cell lines.
Based on the screening data of the novel 4-aryl-3,4-dihydro-2H-1,4-benzoxazines against three cancer cell lines, preliminary SAR conclusions could be drawn (Figure 2). Molecules with OMe (11a–g) are favoured over H (5a–e) on the C7-position of ring A, suggesting that electron-donating substitution on R1 improved activities. For R2 substitution on ring B, the introduction of 4-F, 4-OMe, and 2,4-dimethyl (5c–e and 11a–g) lead to general antiproliferative improvements when compared to an unsubstituted ring (5a and 5b). Among these three substitutions, compounds with 4-OMe (11a and 11b, 91% and 44% against MIA PaCa-2, respectively) and 2,4-dimethyl (11d, 48%) were favoured over 4-F (11f and 11g, 33% and 12%). These results suggested that the introduction of electron-donating groups at the para-position on ring B gave rise to stronger anti-cancer activities than electron-withdrawing para-substituents. Meanwhile, no significant difference was observed between 4-OMe and 2,4-dimethyl substituents, suggesting that the anticancer activities might be independent of the strength of the electron-donating groups. However, it should be noted that the introduction of an extra electron-donating methyl group at the 2-position could influence the overall anticancer activity of the compound. The demethylated analogues (14a–g) displayed superior efficacy over their methylated precursors (13b–e), suggesting that the presence of hydroxyl groups is beneficial for anticancer activity, with the exception being compound 14e, which displayed no activity against all tested cell lines. The overall increased activity due to the presence of the hydroxyl groups could be attributed to hydrogen bonding interactions towards the potential binding site. This observation is supported by the binding of genistein, an isoflavone with two hydroxyl groups which allows it to bind to the estrogen receptors, thus exerting its effects against hormone-dependent cancers [24]. Compound 14f with 4-NH2 at R3 exhibited significant improvement on inhibition against MDA-MB-231 (78%) and PC-3 (98%) cell lines when compared to other series, leading us to identify the 4-NH2 on ring C as a crucial substitution for increasing overall efficacy. It is hypothesized that this class of compounds exhibits anticancer activity with a mechanism similar to those of isoflavones. The precise mechanism of the anticancer activity remains to be explored.
Compound 14f (Figure 3) which exhibited 95% inhibition against MIA PaCa-2 and PC-3 and around 90% inhibition against the MDA-MB-231 cell line at 25 µM was selected as the lead compound to determine the IC50 values in the concentration range of 0.002–50 μM. The IC50 values were found to be 9.71, 7.84, 12.9, 9.58, and 16.2 μM corresponding to PC-3, NHDF, MDA-MB-231, MIA PaCa-2, and U-87 MG cancer cells, respectively. The IC50 values of a structurally similar anticancer agent Cantrixil were found to be 0.096, 3.72 and 0.205 μM for PC-3, MIA PaCa-2, and U-87 MG cancer cells, respectively [25]. The predicted physiochemical properties of the tested compounds were calculated using online software [26]. The significant parameters can be used as guidance to determine whether these compounds obey the Lipinski rule of five (description of the rule is provided in Table 2). The parameters of all the tested compounds fall within range of the Lipinski rule of five, suggesting these compounds potentially possess good oral bioavailability.

3. Materials and Methods

General procedures
All reagents and solvents were obtained from commercial sources and purified if necessary. Melting points were measured using a Mel-Temp melting point apparatus and are uncorrected. Melting points were measured using an OptiMelt melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded using a Cary 630 FTIR spectrometer or NicoletTM iSTM 10 FTIR spectrometer (Thermo Nicolet, Waltham, MA, USA) fitted with a diamond attenuated total reflectance (ATR) sample interface. 1H and 13C NMR spectra were obtained in the specified solvents on a Bruker Avance III HD 400 (Bruker, Sydney, NSW, Australia). Chemical shifts (δ) are in parts per million (ppm) internally referenced to the solvent nuclei. Multiplicities are assigned as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m) or a combination of these (e.g., dd, dt, td), and coupling constants (J) are reported in Hertz (Hz). High-resolution mass spectrometry (HRMS) was performed using a Thermo LTQ Orbitrap XL instrument (Thermo Scientific, Waltham, MA, USA). 1H and 13C NMR spectra of the synthesised compounds are available in the Supplementary Materials. Thin-layer chromatography (TLC) was performed using 0.25 mm silica gel plates (60F-254). The products were purified by column chromatography on silica gel 60 (63–200 mesh).
In vitro assay
Cytotoxicity was determined using a CellTitre-Glo assay [27]. A stock solution of each compound was prepared at 10 mM in DMSO. IC50 values were determined by testing cell growth inhibition across 10 compound concentrations, starting at 50 μM and using 3-fold serial dilution in a 96-well plate. Each compound concentration was tested in duplicate in two independent experiments. DMSO final concentration was normalised at 0.5%. Plates were incubated for 72 h at 37 °C and 5% CO2. During data analysis, IC50 values were calculated with KLFit curve fitting software (version 5.5.0.5) using the 4 Parameter Logistic Model [fit = (A + ((B−A)/(1 + ((C/x)^D))))] (A: Bottom; B: Top; C: Relative IC50; D: Hill).

Experimental Protocols and Analytical Details

General procedure for the synthesis of 2-nitrophenoxyphenylethanones
Anhydrous K2CO3 (1.8 eq.) was added to a stirred solution of the corresponding 2-nitrophenol in acetone at room temperature and stirred for 30 min. The corresponding 2-bromo-1-phenylethanone (1.1 eq.) was added to the reaction mixture and stirred at room temperature until the reaction showed signs of completion as indicated by TLC. The reaction mixture was filtered, and the residue was washed with acetone. The combined filtrate was concentrated in vacuo to obtain the crude product. Acetone was added followed by the slow addition of H2O until solid precipitated out. The solid thus obtained was filtered and dried to obtain the target 2-nitrophenoxyphenylethanone.
2-(2-Nitrophenoxy)-1-phenylethan-1-one (3a). Pale brown solid, yield: 83%. 1H NMR (400 MHz, DMSO-d6) δ 8.05–7.98 (m, 2H), 7.90 (dd, J = 8.1, 1.7 Hz, 1H), 7.76–7.67 (m, 1H), 7.63–7.54 (m, 3H), 7.30 (dd, J = 8.6, 1.1 Hz, 1H), 7.13 (m, 1H), 5.87 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 194.06, 151.17, 140.15, 134.53, 134.46, 129.32, 128.38, 125.36, 121.38, 115.85, 71.54. Data consistent with reported literature [28].
1-(4-Methoxyphenyl)-2-(2-nitrophenoxy)ethan-1-one (3b). White solid, yield: 72%. 1H NMR (400 MHz, DMSO-d6) δ 8.03–7.94 (m, 2H), 7.89 (dd, J = 8.1, 1.7 Hz, 1H), 7.58 (ddd, J = 8.6, 7.4, 1.7 Hz, 1H), 7.25 (dd, J = 8.6, 1.1 Hz, 1H), 7.17–7.05 (m, 3H), 5.79 (s, 2H), 3.87 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 192.32, 164.21, 151.28, 140.12, 134.51, 130.76, 127.41, 125.35, 121.29, 115.83, 114.57, 71.23, 56.14. Data consistent with reported literature [28].
2-(5-Methoxy-2-nitrophenoxy)-1-(4-methoxyphenyl)ethan-1-one (8a). Pale brown solid, yield: 62%, mp: 147–149 °C. IR (neat) 1681, 1290, 1172 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.03–7.93 (m, 3H), 7.14–7.05 (m, 2H), 6.75 (d, J = 2.5 Hz, 1H), 6.69 (dd, J = 9.1, 2.5 Hz, 1H), 5.80 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 192.26, 164.64, 164.19, 154.26, 133.21, 130.81, 128.23, 127.49, 114.55, 106.47, 101.69, 71.39, 56.63, 56.13. HRMS (+ESI): Found m/z 340.07910, [M + Na]+. C16H15NO6Na [340.07971].
1-(2,4-Dimethylphenyl)-2-(5-methoxy-2-nitrophenoxy)ethan-1-one (8b). Pale yellow solid, yield: 90%, mp: 124–126 °C. IR (neat) 2925, 1679, 1261 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 9.1 Hz, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.19 (d, J = 8.9 Hz, 2H), 6.78–6.63 (m, 2H), 5.70 (s, 2H), 3.82 (s, 3H), 2.39 (s, 3H), 2.34 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 196.66, 164.63, 154.19, 143.05, 138.76, 133.09, 131.94, 129.79, 128.22, 126.89, 106.68, 101.35, 72.42, 56.63, 21.45, 21.28. HRMS (+ESI): Found m/z 338.09992, [M + Na]+. C17H17NO5Na [338.10044].
1-(4-Fluorophenyl)-2-(5-methoxy-2-nitrophenoxy)ethan-1-one (8c). White solid, yield: 79%, mp: 173–175 °C. IR (neat) 1684, 1592, 1501 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.15–8.05 (m, 2H), 7.99 (d, J = 9.1 Hz, 1H), 7.48–7.37 (m, 2H), 6.80 (d, J = 2.5 Hz, 1H), 6.70 (dd, J = 9.1, 2.5 Hz, 1H), 5.85 (s, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 192.64, 167.14, 164.68, 164.63, 154.10, 133.21, 131.58, 131.48, 131.41, 131.38, 128.24, 116.49, 116.27, 106.57, 101.72, 71.61, 56.66. HRMS (+ESI): Found m/z 328.05918, [M + Na]+. C15H12FNO5Na [328.05972].
General procedure for the synthesis of 1,4-benzoxazines
Palladium on carbon (10% wt, 0.1 eq) was added to a solution of the corresponding 2-nitrophenoxyphenylethanone in methanol at room temperature and stirred for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain the target 1,4-benzoxazine.
3-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (4a). Pale yellow oil, yield: 50%. 1H NMR (400 MHz, DMSO-d6) δ 7.49–7.26 (m, 5H), 6.78–6.66 (m, 3H), 6.59–6.47 (m, 1H), 6.26 (s, 1H), 4.47 (dt, J = 7.3, 2.4 Hz, 1H), 4.22 (ddd, J = 10.5, 3.1, 1.6 Hz, 1H), 3.90 (dd, J = 10.5, 7.5 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 142.70, 140.14, 134.92, 128.39, 127.63, 127.13, 121.19, 116.87, 115.74, 114.89, 69.91, 52.75. Data consistent with reported literature [29].
3-(4-Methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (4b). Pale yellow oil, yield: 96%. 1H NMR (400 MHz, DMSO-d6) δ 7.39–7.31 (m, 2H), 7.00–6.91 (m, 2H), 6.76–6.68 (m, 3H), 6.53 (ddd, J = 7.6, 5.2, 3.8 Hz, 1H), 6.17 (d, J = 1.7 Hz, 1H), 4.41 (dt, J = 7.5, 2.3 Hz, 1H), 4.19 (ddd, J = 10.4, 3.0, 1.7 Hz, 1H), 3.86 (dd, J = 10.4, 7.9 Hz, 1H), 3.76 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 159.36, 143.19, 135.51, 132.36, 128.75, 121.58, 117.35, 116.19, 115.41, 114.29, 70.60, 55.57, 52.69. Data consistent with reported literature [30].
7-Methoxy-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (9a). Pale yellow solid, yield: 60%, mp: 147–149 °C. IR (neat) 3327, 2837, 1507 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.39–7.30 (m, 2H), 6.98–6.90 (m, 2H), 6.69–6.56 (m, 1H), 6.40–6.31 (m, 2H), 5.74 (t, J = 1.8 Hz, 1H), 4.31 (dt, J = 8.1, 2.3 Hz, 1H), 4.16 (ddd, J = 10.4, 2.9, 1.8 Hz, 1H), 3.84 (dd, J = 10.4, 8.2 Hz, 1H), 3.75 (s, 3H), 3.63 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.84, 151.65, 143.40, 131.91, 128.65, 128.31, 115.65, 113.79, 106.70, 102.11, 70.51, 55.27, 55.11, 52.33. HRMS (+ESI): Found m/z 272.12811, [M + H]+. C16H18NO3 [272.12867].
3-(2,4-Dimethylphenyl)-7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (9b). White solid, yield: 95%, mp: 122–124 °C. IR (neat) 3348, 2872, 1504 cm−1. 1H NMR (400 MHz, DMSO) δ 7.31–7.24 (m, 1H), 7.06–6.99 (m, 2H), 6.65–6.58 (m, 1H), 6.39–6.31 (m, 2H), 5.61 (t, J = 1.9 Hz, 1H), 4.48 (dt, J = 8.2, 2.4 Hz, 1H), 4.18 (ddd, J = 10.6, 2.9, 2.0 Hz, 1H), 3.74 (dd, J = 10.5, 8.3 Hz, 1H), 3.63 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H). 13C NMR (101 MHz, DMSO) δ 151.64, 143.37, 136.30, 135.13, 134.64, 130.89, 128.96, 126.73, 126.70, 115.74, 106.70, 102.12, 69.19, 55.29, 49.24, 20.57, 18.66. HRMS (+ESI): Found m/z 270.14885, [M + H]+. C17H20NO2 [270.14940].
3-(4-Fluorophenyl)-7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (9c). Brown solid: 92%, mp: 122–124 °C. IR (neat) 3363, 2860, 1507 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.51–7.41 (m, 2H), 7.26–7.15 (m, 2H), 6.63 (dt, J = 8.6, 1.2 Hz, 1H), 6.40–6.33 (m, 2H), 5.84 (t, J = 1.8 Hz, 1H), 4.40 (dt, J = 7.9, 2.4 Hz, 1H), 4.19 (ddd, J = 10.5, 2.9, 1.7 Hz, 1H), 3.87 (dd, J = 10.4, 7.8 Hz, 1H), 3.64 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.32, 160.90, 152.19, 143.88, 136.86, 136.84, 129.65, 129.57, 128.84, 116.17, 115.68, 115.47, 107.32, 102.63, 70.68, 55.74, 52.62. HRMS (+ESI): Found m/z 260.10818, [M + H]+. C15H15FNO2 [260.10868].
7-Methoxy-3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine (10a). White solid: 40%, mp: 128–130 °C. IR (neat) 2970, 2921, 2842 cm−1. 1H NMR (400 MHz, DMSO) δ 7.98–7.90 (m, 2H), 7.25 (d, J = 8.5 Hz, 1H), 7.09–7.01 (m, 2H), 6.59 (dd, J = 8.5, 2.7 Hz, 1H), 6.53 (d, J = 2.7 Hz, 1H), 5.12 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H). 13C NMR (101 MHz, DMSO) δ 161.91, 159.61, 156.10, 147.58, 128.53, 128.21, 128.05, 114.55, 108.28, 101.45, 62.68, 55.92, 55.86. HRMS (+ESI): Found m/z 270.11239, [M + H]+. C16H16NO3 [270.11302].
3-(4-Fluorophenyl)-7-methoxy-2H-benzo[b][1,4]oxazine (10b). Yellow crystal: 5%, mp: 145–147 °C. IR (neat) 2966, 1587, 1306 cm−1. 1H NMR (400 MHz, DMSO) δ 8.09–7.97 (m, 2H), 7.38–7.31 (m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 6.61 (dd, J = 8.6, 2.7 Hz, 1H), 6.54 (d, J = 2.6 Hz, 1H), 5.16 (s, 2H), 3.77 (s, 3H). 13C NMR (101 MHz, DMSO) δ 165.38, 162.90, 160.08, 155.60, 147.61, 132.11, 132.08, 129.28, 129.20, 128.59, 127.75, 116.27, 116.05, 108.41, 101.47, 62.78, 55.97. HRMS (+ESI): Found m/z 258.09252, [M + H]+. C15H13FNO2 [258.09303].
General procedure A for the synthesis of 3,4-diphenyl-1,4-benzoxazines
A Schlenk flask was charged with caesium carbonate (1.4 eq.), the corresponding 1,4-benzoxazine, and bromophenol (1.6 eq.). The flask was vacuumed and backfilled with nitrogen three times before the reaction mixture was dissolved in toluene and tert-butanol and stirred for 10 min at room temperature. Pd2(dba)3 (0.02 eq.) and XPhos (0.1 eq.) were added to the solution and the mixture was refluxed until the reaction showed signs of completion as indicated by TLC. The mixture was cooled to room temperature and diluted with ethyl acetate. The solution was washed with brine and water before being dried with sodium sulphate and concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain the target 3,4-diphenyl-1,4-benzoxazine.
General procedure B for the synthesis of 3,4-diphenyl-1,4-benzoxazines
A Schlenk flask was charged with potassium tert-butoxide (1.5 eq.), the corresponding 1,4-benzoxazine, and bromophenol (1.6 eq.). The flask was vacuumed and back filled with nitrogen for three times before the reaction mixture was dissolved in toluene and stirred for 10 min at room temperature. Palladium acetate (0.05 eq.) and tri-tert-butylphosphine (0.1 eq.) was added to the solution and the mixture was refluxed until the reaction showed signs of completion as indicated by TLC. The mixture was cooled to room temperature and diluted with ethyl acetate. The solution was washed with brine and water before drying with sodium sulphate and then concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain target 3,4-diphenyl-1,4-benzoxazine.
3,4-Diphenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (5a). White solid, yield: 50%, mp: 166–168 °C. IR (neat) 2936, 2167, 1493 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.37–7.26 (m, 6H), 7.27–7.16 (m, 3H), 7.12–7.03 (m, 1H), 6.87 (dd, J = 8.1, 1.6 Hz, 1H), 6.83–6.72 (m, 2H), 6.69 (td, J = 7.5, 1.6 Hz, 1H), 5.05 (t, J = 3.1 Hz, 1H), 4.48 (dd, J = 11.0, 3.3 Hz, 1H), 4.30 (dd, J = 11.0, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 146.25, 144.65, 140.33, 132.83, 129.93, 128.87, 127.67, 127.40, 124.50, 124.48, 121.74, 119.73, 117.22, 116.19, 68.86, 60.66. HRMS (+ESI): Found m/z 288.13830, [M + H]+. C20H18NO [288.13884].
4-(4-Nitrophenyl)-3-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (5b). Orange solid, yield: 43%, mp: 167–169 °C. IR (neat) 2928, 1583, 1490 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.23–8.14 (m, 2H), 7.45–7.36 (m, 1H), 7.40–7.30 (m, 6H), 7.27 (ddd, J = 9.7, 5.1, 2.3 Hz, 1H), 6.96–6.86 (m, 2H), 6.87–6.79 (m, 1H), 5.37 (d, J = 2.4 Hz, 1H), 4.78 (dd, J = 11.4, 2.0 Hz, 1H), 4.39 (dd, J = 11.4, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 152.11, 146.10, 141.02, 138.60, 129.16, 128.01, 127.88, 126.95, 126.08, 123.47, 121.63, 119.66, 119.57, 117.87, 68.32, 59.16. HRMS (+ESI): Found m/z 333.12349, [M + H]+. C20H17N2O3 [333.12392].
3-(4-Methoxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (5c). Pale yellow crystal, yield: 47%, mp: 152–154 °C. IR (neat) 2906, 1489, 1248 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.38–7.27 (m, 2H), 7.21 (ddd, J = 15.6, 7.6, 1.7 Hz, 4H), 7.12–7.03 (m, 1H), 6.89–6.64 (m, 6H), 4.97 (t, J = 3.3 Hz, 1H), 4.42 (dd, J = 10.9, 3.8 Hz, 1H), 4.26 (dd, J = 10.9, 2.8 Hz, 1H), 3.70 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.86, 146.20, 144.63, 133.08, 131.96, 129.89, 128.63, 124.72, 124.53, 121.66, 119.65, 117.15, 116.15, 114.27, 69.04, 60.01, 55.46. HRMS (+ESI): Found m/z 318.14909, [M + H]+. C21H20NO2 [318.14940].
3-(4-Methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (5d). Orange solid, yield: 50%, mp: 107–109 °C. IR (neat) 2833, 2161, 2044 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.23–8.14 (m, 2H), 7.43–7.31 (m, 3H), 7.30–7.23 (m, 2H), 6.92–6.81 (m, 5H), 5.28 (d, J = 2.6 Hz, 1H), 4.72 (dd, J = 11.4, 2.1 Hz, 1H), 4.36 (dd, J = 11.4, 2.8 Hz, 1H), 3.71 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.54, 151.62, 145.63, 140.48, 129.75, 127.68, 127.54, 125.59, 122.96, 121.08, 119.16, 119.06, 117.36, 114.10, 67.90, 58.15, 55.05. HRMS (+ESI): Found m/z 363.13424, [M + H]+. C21H19N2O4 [363.13448].
4-(4-Fluorophenyl)-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (5e). Pale yellow solid, yield: 23%, mp: 101–103 °C. IR (neat) 2928, 1495, 1213 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.25–7.11 (m, 9H), 6.88–6.78 (m, 3H), 6.78–6.63 (m, 2H), 6.61 (dd, J = 7.9, 1.7 Hz, 1H), 4.91 (dd, J = 4.5, 2.9 Hz, 1H), 4.36 (dd, J = 10.9, 4.6 Hz, 1H), 4.27 (dd, J = 10.9, 2.9 Hz, 1H), 3.70 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.95, 144.43, 142.26, 142.23, 134.20, 131.59, 131.24, 131.16, 128.88, 128.11, 128.03, 121.76, 119.38, 117.06, 116.74, 116.52, 115.99, 115.78, 115.54, 114.27, 69.33, 60.26, 55.45. HRMS (+ESI): Found m/z 336.13957, [M + H]+. C21H19FNO2 [336.13998].
7-Methoxy-3-(4-methoxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (11a). Orange oil, yield: 38%. IR (neat) 2935, 2836, 1502 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.86–7.76 (m, 1H), 7.52–7.42 (m, 1H), 7.31–7.24 (m, 3H), 7.17–7.09 (m, 2H), 6.99 (tt, J = 7.2, 1.2 Hz, 1H), 6.89–6.81 (m, 2H), 6.45–6.37 (m, 2H), 4.93 (t, 1H), 4.50 (dd, J = 11.0, 3.3 Hz, 1H), 4.21 (dd, J = 11.0, 2.8 Hz, 1H), 3.70 (s, 3H), 3.65 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.80, 153.82, 147.64, 145.91, 131.76, 129.81, 128.54, 125.26, 123.23, 122.84, 118.82, 114.26, 107.71, 102.75, 68.44, 59.80, 55.67, 55.47. HRMS (+ESI): Found m/z 348.15951, [M + H]+. C22H22NO3 [348.15997].
7-Methoxy-3,4-bis(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11b). Red oil, yield: 82%. IR (neat) 2931, 1596, 1501 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.27–7.19 (m, 2H), 7.11–7.03 (m, 2H), 6.90–6.79 (m, 4H), 6.48 (d, J = 8.9 Hz, 1H), 6.42 (d, J = 2.8 Hz, 1H), 6.35 (dd, J = 8.9, 2.8 Hz, 1H), 4.79 (dd, J = 5.0, 2.8 Hz, 1H), 4.34 (dd, J = 10.9, 5.0 Hz, 1H), 4.21 (dd, J = 10.9, 2.9 Hz, 1H), 3.70 (d, J = 1.2 Hz, 6H), 3.64 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.86, 156.48, 153.01, 145.24, 140.07, 131.73, 128.97, 128.48, 127.17, 117.18, 115.06, 114.17, 107.52, 102.82, 69.37, 60.42, 55.71, 55.61, 55.44. HRMS (+ESI): Found m/z 378.16984, [M + H]+. C23H24NO4 [378.17053].
7-Methoxy-3-(4-methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11c). Red oil, yield: 24%. IR (neat) 2923, 1598, 1495 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.20–8.11 (m, 2H), 7.31–7.24 (m, 5H), 6.94–6.85 (m, 2H), 6.52 (dd, J = 9.0, 2.8 Hz, 1H), 6.42 (d, J = 2.8 Hz, 1H), 5.31 (s, 1H), 4.77 (dd, J = 11.5, 1.9 Hz, 1H), 4.33 (dd, J = 11.4, 2.8 Hz, 1H), 3.70 (d, J = 11.3 Hz, 6H). 13C NMR (101 MHz, DMSO-d6) δ 158.99, 156.12, 152.65, 147.36, 140.08, 129.91, 128.20, 126.20, 121.76, 120.43, 118.10, 114.54, 108.03, 102.68, 68.25, 58.23, 55.73, 55.53. HRMS (+ESI): Found m/z 393.14461, [M + H]+. C22H21N2O5 [393.14505].
3-(2,4-Dimethylphenyl)-7-methoxy-4-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11d). Light brown gum, yield: 38%. IR (neat) 2921, 1586, 1501 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.18–7.13 (m, 1H), 7.13–7.06 (m, 2H), 6.89 (d, J = 6.7 Hz, 2H), 6.87–6.81 (m, 2H), 6.46 (dd, J = 7.9, 2.8 Hz, 1H), 6.38 (d, J = 8.8 Hz, 1H), 6.33 (dd, J = 8.9, 2.7 Hz, 1H), 5.00 (dd, J = 5.9, 3.0 Hz, 1H), 4.25 (dd, J = 11.0, 3.1 Hz, 1H), 4.17 (dd, J = 11.0, 5.9 Hz, 1H), 3.69 (s, 3H), 3.65 (s, 3H), 2.24 (s, 3H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 156.90, 152.66, 144.90, 139.31, 136.50, 135.29, 134.41, 131.49, 130.19, 128.28, 128.09, 126.96, 115.96, 115.01, 107.40, 102.94, 69.02, 57.27, 55.75, 55.56, 20.97, 19.25. HRMS (+ESI): Found m/z 376.19085, [M + H]+. C24H26NO3 [376.19127].
3-(2,4-Dimethylphenyl)-7-methoxy-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11e). Red solid, yield: 78%, mp: 121–123 °C. IR (neat) 2929, 1585, 1493 cm−1. 1H NMR (400 MHz, Chloroform-d) δ 8.15–8.06 (m, 2H), 7.30 (d, J = 8.6 Hz, 1H), 7.19–7.12 (m, 2H), 7.09–7.06 (m, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.94–6.87 (m, 1H), 6.61–6.53 (m, 2H), 5.11 (t, J = 3.6 Hz, 1H), 4.47–4.39 (m, 1H), 4.35 (dd, J = 11.0, 3.5 Hz, 1H), 3.81 (s, 3H), 2.42 (s, 3H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 155.74, 152.55, 147.71, 141.04, 137.72, 133.65, 133.30, 132.04, 127.42, 126.61, 125.55, 122.89, 119.79, 118.57, 108.20, 103.00, 68.33, 58.86, 55.60, 31.60, 22.67, 20.97, 19.29, 14.14. HRMS (+ESI): Found m/z 391.16525, [M + H]+. C23H23N2O4 [391.16578].
3-(2,4-Dimethylphenyl)-7-methoxy-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (15a). Yellow solid, yield: 55%, mp: 112–114 °C. IR (neat) 2923, 1587, 1505 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.79 (d, J = 2.6 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 8.3, 1.4 Hz, 1H), 7.63 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.95 (d, J = 1.8 Hz, 1H), 6.91–6.82 (m, 1H), 6.76 (d, J = 8.9 Hz, 1H), 6.53 (d, J = 2.9 Hz, 1H), 6.43 (dd, J = 8.9, 2.9 Hz, 1H), 5.32 (d, J = 3.7 Hz, 1H), 4.41–4.26 (m, 2H), 3.69 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 153.93, 149.67, 145.91, 144.82, 140.22, 136.84, 135.37, 134.10, 131.80, 128.95, 128.71, 128.65, 128.36, 127.89, 127.63, 127.40, 127.24, 127.06, 116.96, 107.83, 103.22, 68.51, 57.39, 55.79, 20.94, 19.33. HRMS (+ESI): Found m/z 397.19073, [M + H]+. C26H25N2O2 [397.19160].
3-(4-Fluorophenyl)-7-methoxy-4-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11f). Yellow oil, yield: 83%. IR (neat) 2938, 2835, 1501 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.41–7.31 (m, 2H), 7.16–7.03 (m, 4H), 6.91–6.82 (m, 2H), 6.53 (d, J = 8.9 Hz, 1H), 6.44 (d, J = 2.8 Hz, 1H), 6.37 (dd, J = 8.9, 2.8 Hz, 1H), 4.88 (t, J = 3.7 Hz, 1H), 4.38 (dd, J = 10.9, 4.6 Hz, 1H), 4.24 (dd, J = 10.9, 2.8 Hz, 1H), 3.70 (s, 3H), 3.65 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.00, 160.58, 156.54, 153.13, 145.23, 140.07, 136.26, 136.23, 129.80, 129.72, 128.03, 127.03, 117.37, 115.65, 115.44, 115.13, 107.72, 102.86, 68.99, 60.48, 55.70, 55.62. HRMS (+ESI): Found m/z 388.13199, [M + Na]+. C22H20FNO3Na [388.13249].
3-(4-Fluorophenyl)-7-methoxy-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (11g). Yellow solid, yield: 33%, mp: 139–141 °C. IR (neat) 2912, 1589, 1494 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.21–8.08 (m, 2H), 7.45–7.36 (m, 2H), 7.35–7.24 (m, 3H), 7.24–7.12 (m, 2H), 6.53 (dd, J = 9.0, 2.8 Hz, 1H), 6.43 (d, J = 2.8 Hz, 1H), 5.38 (s, 1H), 4.81 (dd, J = 11.5, 1.9 Hz, 1H), 4.34 (dd, J = 11.5, 2.8 Hz, 1H), 3.69 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.10, 160.68, 156.18, 152.65, 147.29, 140.27, 134.45, 134.42, 129.15, 129.07, 126.19, 121.93, 120.24, 118.28, 116.03, 115.82, 108.20, 102.70, 68.09, 58.30, 55.73. HRMS (+ESI): Found m/z 403.10655, [M + Na]+. C21H17FN2O4Na [403.10700].
3-(4-Fluorophenyl)-7-methoxy-2H-benzo[b][1,4]oxazine (12). Dark purple solid: 35%, mp: 159–161 °C. IR (neat) 2989, 2935, 2834 cm−1. 1H NMR (400 MHz, DMSO) δ 7.83–7.72 (m, 2H), 7.34 (d, J = 8.6 Hz, 1H), 7.04–6.93 (m, 2H), 6.72 (d, J = 8.5 Hz, 2H), 6.69 (s, 2H), 6.65 (d, J = 2.4 Hz, 1H), 6.56 (dd, J = 8.6, 2.7 Hz, 1H), 6.36 (d, J = 2.7 Hz, 1H), 6.32 (dd, J = 8.6, 2.4 Hz, 1H), 3.95 (s, 3H), 3.77 (s, 3H), 3.69 (s, 6H). 13C NMR (101 MHz, DMSO) δ 162.12, 161.70, 160.02, 158.53, 156.13, 145.90, 129.79, 128.34, 128.12, 128.07, 127.76, 116.04, 114.59, 108.16, 105.44, 102.18, 99.64, 66.66, 56.49, 55.82, 55.80, 55.70. HRMS (+ESI): Found m/z 406.16517, [M + H]+. C24H24NO5 [406.16545].
3-(4-Fluorophenyl)-7-methoxy-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (15b). Brown gum, yield: 67%. IR (neat) 3078, 3002, 1507 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 2.6 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.61 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.55–7.44 (m, 3H), 7.21–7.11 (m, 2H), 7.02–6.95 (m, 1H), 6.51–6.44 (m, 2H), 5.26 (s, 1H), 4.64 (dd, J = 11.2, 3.1 Hz, 1H), 4.34 (dd, J = 11.2, 2.7 Hz, 1H), 3.69 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.07, 160.65, 154.77, 148.15, 146.49, 144.34, 141.22, 135.56, 135.53, 129.55, 129.47, 128.94, 128.79, 128.16, 127.70, 127.49, 125.34, 123.92, 119.52, 115.88, 115.67, 108.20, 102.96, 67.97, 59.71, 55.72. HRMS (+ESI): Found m/z 387.15037, [M + H]+. C24H20FN2O2 [387.15088].
General procedure for the synthesis of 3-phenyl-4-aniline-1,4-benzoxazine
Palladium on carbon (10% wt, 0.1 eq.) was added to a solution of the corresponding 3-phenyl-4-aniline-1,4-benzoxazine in methanol at room temperature and stirred for 16 h. The reaction mixture was filtered through celite and the filtrate removed in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain target 3-phenyl-4-aniline-1,4-benzoxazine.
4-(3-Phenyl-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (13a). Brown solid, yield: 85%, mp: 169–171 °C. IR (neat) 3454, 3374, 2920 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.33–7.15 (m, 5H), 6.89–6.81 (m, 2H), 6.76 (dd, J = 7.8, 1.5 Hz, 1H), 6.68 (ddd, J = 8.0, 7.3, 1.6 Hz, 1H), 6.57 (td, J = 7.6, 1.6 Hz, 1H), 6.53–6.41 (m, 3H), 5.00 (s, 2H), 4.83 (t, J = 3.8 Hz, 1H), 4.32–4.21 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 146.59, 143.41, 140.24, 135.86, 133.58, 128.20, 127.96, 127.38, 127.17, 121.34, 117.26, 116.16, 114.52, 114.15, 69.15, 61.04. HRMS (+ESI): Found m/z 303.14921, [M + H]+. C20H19N2O [303.14974].
4-(3-(4-Methoxyphenyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (13b). Yellow solid, yield: 78%, mp: 170–172 °C. IR (neat) 3456, 3371, 2932 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.23–7.15 (m, 2H), 6.87–6.79 (m, 4H), 6.76 (dd, J = 7.8, 1.6 Hz, 1H), 6.71–6.62 (m, 1H), 6.56 (td, J = 7.5, 1.6 Hz, 1H), 6.52–6.44 (m, 2H), 6.41 (dd, J = 8.0, 1.5 Hz, 1H), 5.00 (s, 2H), 4.75 (t, J = 4.0 Hz, 1H), 4.22 (d, J = 4.0 Hz, 2H), 3.70 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.85, 147.04, 143.91, 136.60, 133.99, 132.29, 129.07, 128.59, 121.72, 117.74, 116.56, 114.98, 114.73, 114.07, 69.87, 60.74, 55.42. HRMS (+ESI): Found m/z 333.15971, [M + H]+. C21H21N2O2 [333.16030].
4-(7-Methoxy-3-(4-methoxyphenyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (13c). Dark-brown solid, yield: 100%, mp: 142–144 °C. IR (neat) 3448, 2929, 2837 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.28–7.13 (m, 2H), 6.88–6.73 (m, 4H), 6.50–6.42 (m, 2H), 6.42–6.25 (m, 3H), 4.93 (s, 2H), 4.68 (dd, J = 5.6, 3.0 Hz, 1H), 4.32–4.13 (m, 2H), 3.70 (s, 3H), 3.63 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 158.82, 152.40, 146.54, 144.82, 135.40, 132.00, 130.17, 129.14, 127.96, 116.46, 114.98, 114.05, 107.33, 102.75, 69.89, 60.59, 55.72, 55.41. HRMS (+ESI): Found m/z 363.17036, [M + H]+. C22H23N2O3 [363.17087].
4-(3-(2,4-Dimethylphenyl)-7-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (13d). Brown solid, yield: 75%, mp: 119–121 °C. IR (neat) 3466, 3377, 2883 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 7.17 (d, J = 7.8 Hz, 1H), 6.93–6.85 (m, 2H), 6.86–6.78 (m, 2H), 6.48–6.37 (m, 3H), 6.30 (d, J = 1.6 Hz, 2H), 4.94 (s, 2H), 4.91 (dd, J = 6.4, 3.0 Hz, 1H), 4.22 (dd, J = 10.9, 3.0 Hz, 1H), 4.12 (dd, J = 10.9, 6.4 Hz, 1H), 3.64 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 152.21, 146.82, 144.62, 136.36, 135.33, 134.85, 134.56, 131.40, 131.35, 128.52, 128.30, 126.89, 115.76, 114.95, 107.23, 102.83, 69.29, 57.17, 55.75, 20.99, 19.26. HRMS (+ESI): Found m/z 361.19108, [M + H]+. C23H25N2O2 [361.19160].
4-(3-(4-Fluorophenyl)-7-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (13e).
Dark-brown solid, yield: 43%, mp: 128–130 °C. IR (neat) 3455, 3364, 2836 cm−1. 1H NMR (400 MHz, Chloroform-d) δ 7.32–7.23 (m, 2H), 7.04–6.93 (m, 2H), 6.97–6.89 (m, 2H), 6.65–6.57 (m, 3H), 6.52 (d, J = 2.8 Hz, 1H), 6.39 (dd, J = 8.9, 2.8 Hz, 1H), 4.68 (dd, J = 5.1, 3.1 Hz, 1H), 4.37 (dd, J = 10.8, 5.1 Hz, 1H), 4.31 (dd, J = 10.8, 3.1 Hz, 1H), 3.75 (s, 3H), 3.64 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 163.35, 160.91, 152.98, 144.97, 143.41, 138.35, 135.41, 135.38, 129.16, 129.08, 128.72, 127.54, 117.25, 116.08, 115.46, 115.24, 107.56, 102.61, 69.38, 61.52, 55.67. HRMS (+ESI): Found m/z 351.15036, [M + H]+. C21H20FN2O2 [351.15088].
General procedure for demethylation using BBr3
BBr3 (1M) in dichloromethane solution (2 eq. per methoxy group) was added to a solution of the corresponding methylated 3,4-diphenyl-1,4-benzoxazine in dichloromethane at 0 °C and stirred for 12 h. The reaction mixture was quenched with saturated sodium bicarbonate solution and diluted with ethyl acetate. The solution was washed with brine and water before drying with sodium sulphate and concentrated in vacuo to obtain crude product, which was purified by flash chromatography (dichloromethane/methanol) to obtain target demethylated 3,4-diphenyl-1,4-benzoxazine.
4-(4-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)phenol (14a). White solid, yield: 67%, mp: 150–152 °C. IR (neat) 3516, 1586, 1490 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 7.37–7.27 (m, 2H), 7.22–7.14 (m, 2H), 7.14–7.03 (m, 3H), 6.83–6.62 (m, 6H), 4.90 (t, J = 3.3 Hz, 1H), 4.38 (dd, J = 10.9, 3.9 Hz, 1H), 4.25 (dd, J = 10.9, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 156.97, 146.22, 144.62, 133.29, 130.12, 129.85, 128.62, 124.92, 124.55, 121.61, 119.53, 117.10, 116.08, 115.59, 69.13, 60.10. HRMS (+ESI): Found m/z 304.13317, [M + H]+. C20H18NO2 [304.13375].
4-(4-(4-Aminophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)phenol (14b). Brown solid, yield: 62%, mp: 113–115 °C. IR (neat) 3438, 3352, 2884 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 7.10–7.02 (m, 2H), 6.85–6.77 (m, 2H), 6.75 (dd, J = 7.8, 1.6 Hz, 1H), 6.69–6.60 (m, 3H), 6.55 (td, J = 7.5, 1.6 Hz, 1H), 6.52–6.44 (m, 2H), 6.39 (dd, J = 8.1, 1.6 Hz, 1H), 4.99 (s, 2H), 4.68 (t, J = 4.1 Hz, 1H), 4.22–4.18 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.95, 146.98, 143.91, 136.72, 134.06, 130.49, 129.04, 128.68, 121.67, 117.65, 116.52, 115.42, 114.97, 114.70, 69.94, 60.84. HRMS (+ESI): Found m/z 319.14402, [M + H]+. C20H19N2O2 [319.14465].
3-(4-Hydroxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (14c). Brown solid, yield: 40%, mp: 129–131 °C. IR (neat) 3189, 3927, 2865 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.92 (s, 1H), 7.31–7.21 (m, 2H), 7.17–7.06 (m, 4H), 6.96 (tt, J = 7.1, 1.1 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 6.71–6.62 (m, 2H), 6.27–6.19 (m, 2H), 4.84 (t, J = 3.0 Hz, 1H), 4.43 (dd, J = 11.0, 3.4 Hz, 1H), 4.16 (dd, J = 11.0, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 156.85, 151.84, 148.11, 146.04, 130.05, 129.69, 128.52, 123.77, 122.78, 122.58, 119.28, 115.54, 108.79, 103.97, 68.27, 59.93. HRMS (+ESI): Found m/z 342.11001, [M + Na]+. C20H17NO3Na [342.11061].
4,4′-(7-Hydroxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-3,4-diyl)diphenol (14d). Black solid, yield: 70%, mp: 91–93 °C. IR (neat) 3023, 2814, 2692 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 9.22 (s, 1H), 8.74 (s, 1H), 7.12–7.04 (m, 2H), 6.95–6.87 (m, 2H), 6.69–6.59 (m, 4H), 6.30 (d, J = 8.7 Hz, 1H), 6.22 (d, J = 2.6 Hz, 1H), 6.15 (dd, J = 8.7, 2.7 Hz, 1H), 4.62 (dd, J = 5.5, 2.9 Hz, 1H), 4.24 (dd, J = 10.8, 5.5 Hz, 1H), 4.14 (dd, J = 10.8, 2.9 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 156.90, 154.62, 150.61, 145.15, 138.92, 130.08, 129.05, 127.88, 127.65, 117.31, 116.23, 115.42, 108.57, 103.88, 69.52, 60.68. HRMS (+ESI): Found m/z 358.10491, [M + Na]+. C20H17NO4Na [358.10553].
4-(4-Aminophenyl)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (14e). Black gum, yield: 75%. IR (neat) 2929, 1596, 1502 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.26 (s, 1H), 8.68 (s, 1H), 7.13–6.99 (m, 2H), 6.82–6.71 (m, 2H), 6.68–6.57 (m, 2H), 6.50–6.39 (m, 2H), 6.28–6.18 (m, 2H), 6.13 (dd, J = 8.7, 2.7 Hz, 1H), 4.89 (s, 2H), 4.56 (dd, J = 5.8, 3.1 Hz, 1H), 4.19 (dd, J = 10.8, 5.8 Hz, 1H), 4.13 (dd, J = 10.8, 3.1 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 156.87, 150.21, 146.30, 144.93, 135.98, 130.24, 129.15, 128.89, 127.94, 116.93, 115.36, 114.92, 108.46, 103.80, 69.87, 60.76. HRMS (+ESI): Found m/z 335.13894, [M + H]+. C20H19N2O3 [335.13957].
4-(4-Aminophenyl)-3-(2,4-dimethylphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (14f). Pale-brown Solid, yield: 89%, mp: 185–187 °C. IR (neat) 3373, 3304, 2920 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.18 (d, J = 7.8 Hz, 1H), 6.94–6.84 (m, 2H), 6.84–6.74 (m, 2H), 6.47–6.37 (m, 2H), 6.24 (d, J = 2.6 Hz, 1H), 6.20 (d, J = 8.7 Hz, 1H), 6.13 (dd, J = 8.7, 2.6 Hz, 1H), 4.91 (s, 2H), 4.86 (dd, J = 6.7, 3.0 Hz, 1H), 4.17 (dd, J = 10.9, 3.0 Hz, 1H), 4.08 (dd, J = 10.9, 6.7 Hz, 1H), 2.22 (s, 3H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 150.05, 146.65, 144.70, 136.28, 135.35, 135.29, 134.57, 131.30, 130.05, 128.47, 128.39, 126.87, 116.20, 114.90, 108.45, 103.85, 69.30, 57.18, 20.99, 19.28. HRMS (+ESI): Found m/z 347.17541, [M + H]+. C22H23N2O2 [347.17595].
3-(4-Fluorophenyl)-4-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (14g). Brown gum, yield: 95%. IR (neat) 3401, 1698, 1502 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.25 (s, 1H), 8.79 (s, 1H), 7.40–7.30 (m, 2H), 7.14–7.04 (m, 2H), 6.97–6.89 (m, 2H), 6.71–6.62 (m, 2H), 6.38 (d, J = 8.7 Hz, 1H), 6.24 (d, J = 2.6 Hz, 1H), 6.19 (dd, J = 8.7, 2.7 Hz, 1H), 4.78 (dd, J = 5.0, 2.8 Hz, 1H), 4.31 (dd, J = 10.9, 5.0 Hz, 1H), 4.18 (dd, J = 10.9, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 162.95, 160.53, 154.68, 150.83, 145.16, 138.95, 136.41, 136.38, 129.89, 129.81, 127.32, 127.17, 117.59, 116.34, 115.55, 115.34, 108.84, 103.95, 68.98, 60.63. HRMS (+ESI): Found m/z 360.10063, [M + Na]+. C20H16FNO3Na [360.10119].
3-(4-Fluorophenyl)-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (15c). Brown gum, yield: 87%. IR (neat) 2923, 2798, 1598 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (s, 1H), 8.84 (d, J = 2.7 Hz, 1H), 7.99–7.85 (m, 2H), 7.88–7.78 (m, 1H), 7.60 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.52 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.51–7.42 (m, 2H), 7.21–7.07 (m, 2H), 6.90 (d, J = 8.7 Hz, 1H), 6.36–6.26 (m, 2H), 5.24 (d, J = 3.1 Hz, 1H), 4.61 (dd, J = 11.2, 3.0 Hz, 1H), 4.30 (dd, J = 11.2, 2.7 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 163.04, 160.63, 153.02, 147.79, 146.65, 143.82, 141.66, 135.59, 135.56, 129.56, 129.48, 128.86, 128.66, 128.07, 127.65, 127.54, 124.89, 122.10, 120.05, 115.83, 115.62, 109.37, 104.22, 67.68, 59.68. HRMS (+ESI): Found m/z 373.13476, [M + H]+. C23H18FN2O2 [373.13523].

4. Conclusions

In summary, we developed a facile and efficient approach to synthesise derivatives of a novel 4-aryl-3,4-dihydro-2H-1,4-benzoxazine scaffold with anticancer activity. A total of 29 novel analogues were designed and synthesised for preliminary biological screening. Ten of the synthesised molecules showed positive results against the proliferation of MIA PaCa-2, MDA-MB-231 and PC-3 cancer cells. Compound 14f was identified as a promising lead molecule for further in-depth studies, and subsequent dose-response experiments revealed IC50 values of 7.84–16.2 µM against a panel of five cancer cell lines. Preliminary SAR studies suggested that hydroxyl groups on rings A and B and a 4-amino group on ring C were important for anticancer activity. However, it should be noted that the 1,4-benzoxazines were synthesised as racemic mixtures in this study. Future investigations could be conducted to understand the effect of chirality on antiproliferative properties. Additionally, the precise mechanism of the anticancer activity remains to be explored. Investigating the effects of these compounds on particular signalling and metabolic systems, such as estrogen receptor, could provide an explanation for the established SAR and generate suggestions for the further structural improvement of these molecules.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29010166/s1, 1H and 13C NMR spectra of the synthesised compounds, and information about the cell lines used.

Author Contributions

Conceptualisation, X.F. and N.K.; methodology, X.F.; formal analysis, X.F.; investigation, X.F.; resources, N.K.; writing—original draft preparation, X.F.; writing—review and editing, D.W., D.S.H.C. and N.K.; supervision, N.K., D.S.B.; funding acquisition, N.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the University of New South Wales, Sydney grant number RG222672.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in article and supplementary material.

Acknowledgments

We thank the BMSF and NMR facilities at UNSW Mark Wainwright Analytical Centre for the structural determination of the synthesised compounds.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
  2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
  3. Viale, P.H. The American Cancer Society’s Facts & Figures: 2020 Edition. J. Adv. Pract. Oncol. 2020, 11, 135–136. [Google Scholar] [CrossRef]
  4. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol. Sci. 2005, 26, 178–182. [Google Scholar] [CrossRef] [PubMed]
  5. Lu, J.J.; Pan, W.; Hu, Y.J.; Wang, Y.T. Multi-target drugs: The trend of drug research and development. PLoS ONE 2012, 7, e40262. [Google Scholar] [CrossRef] [PubMed]
  6. Hawash, M. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. Biomolecules 2022, 12, 1843. [Google Scholar] [CrossRef] [PubMed]
  7. Wähälä, K.; Koskimies, J.K.; Mesilaakso, M.; Salakka, A.K.; Leino, T.K.; Adlercreutz, H. The Synthesis, Structure, and Anticancer Activity of cis- and trans-4′,7-Dihydroxyisoflavan-4-ols. J. Org. Chem. 1997, 62, 7690–7693. [Google Scholar] [CrossRef]
  8. Lund, T.D.; Blake, C.; Bu, L.; Hamaker, A.N.; Lephart, E.D. Equol an isoflavonoid: Potential for improved prostate health, in vitro and in vivo evidence. Reprod. Biol. Endocrinol. 2011, 9, 4. [Google Scholar] [CrossRef]
  9. Wang, X.; McKernan, R.; Kim, K.H.; Alvero, A.B.; Whiting, A.; Thompson, J.A.; Mor, G.; Saif, M.W.; Husband, A.J.; Brown, D.M.; et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs 2011, 22, 719–731. [Google Scholar] [CrossRef]
  10. Christiansen, L.B.; Wenckens, M.; Bury, P.S.; Gissel, B.; Hansen, B.S.; Thorpe, S.M.; Jacobsen, P.; Kanstrup, A.; Jørgensen, A.S.; Nærum, L.; et al. Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor. Bioorg. Med. Chem. Lett. 2002, 12, 17–19. [Google Scholar] [CrossRef]
  11. Stevenson, A.J.; Ager, E.I.; Proctor, M.A.; Škalamera, D.; Heaton, A.; Brown, D.; Gabrielli, B.G. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Sci. Rep. 2018, 8, 5144. [Google Scholar] [CrossRef]
  12. Matralis, A.N.; Katselou, M.G.; Nikitakis, A.; Kourounakis, A.P. Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents. J. Med. Chem. 2011, 54, 5583–5591. [Google Scholar] [CrossRef] [PubMed]
  13. Blattes, E.; Lockhart, B.; Lestage, P.; Schwendimann, L.; Gressens, P.; Fleury, M.-B.; Largeron, M. Novel 2-Alkylamino-1,4-benzoxazine Derivatives as Potent Neuroprotective Agents:  Structure−Activity Relationship Studies. J. Med. Chem. 2005, 48, 1282–1286. [Google Scholar] [CrossRef] [PubMed]
  14. Burton, G.A.; Rehwinkel, H.; Jaroch, S.; Hoelscher, P.; Suelzle, D.; Hillmann, M.; McDonald, F.M. Benzoxazine and Benzothiazine Derivatives and Their Use in Medicine. WO/2000/017173, 30 March 2000. [Google Scholar]
  15. Bollu, R.; Palem, J.D.; Bantu, R.; Guguloth, V.; Nagarapu, L.; Polepalli, S.; Jain, N. Rational design, synthesis and anti-proliferative evaluation of novel 1,4-benzoxazine-[1,2,3]triazole hybrids. Eur. J. Med. Chem. 2015, 89, 138–146. [Google Scholar] [CrossRef]
  16. Das, B.C.; Madhukumar, A.V.; Anguiano, J.; Mani, S. Design, synthesis and biological evaluation of 2H-benzo[b][1,4]oxazine derivatives as hypoxia targeted compounds for cancer therapeutics. Bioorg. Med. Chem. Lett. 2009, 19, 4204–4206. [Google Scholar] [CrossRef] [PubMed]
  17. La, D.S.; Belzile, J.; Bready, J.V.; Coxon, A.; DeMelfi, T.; Doerr, N.; Estrada, J.; Flynn, J.C.; Flynn, S.R.; Graceffa, R.F. Novel 2, 3-dihydro-1, 4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J. Med. Chem. 2008, 51, 1695–1705. [Google Scholar] [CrossRef] [PubMed]
  18. Ilic, M.; Ilas, J.; Dunkel, P.; Matyus, P.; Bohac, A.; Liekens, S.; Kikelj, D. Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis. Eur. J. Med. Chem. 2012, 58, 160–170. [Google Scholar] [CrossRef]
  19. Aicher, T.D.; Van Huis, C.A.; Hurd, A.R.; Skalitzky, D.J.; Taylor, C.B.; Beleh, O.M.; Glick, G.; Toogood, P.L.; Yang, B.; Zheng, T. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer. J. Med. Chem. 2021, 64, 13410–13428. [Google Scholar] [CrossRef]
  20. Dong, F.D.; Liu, D.D.; Deng, C.L.; Qin, X.C.; Chen, K.; Wang, J.; Song, H.R.; Ding, H.W. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kalpha inhibitors. Bioorg. Med. Chem. 2018, 26, 3982–3991. [Google Scholar] [CrossRef]
  21. Yan, G.; Pu, C.; Lan, S.; Zhong, X.; Zhou, M.; Hou, X.; Yang, J.; Shan, H.; Zhao, L.; Li, R. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. Eur. J. Med. Chem. 2019, 178, 667–686. [Google Scholar] [CrossRef]
  22. Jana, A.K.; Singh, J.; Ganesher, A.; Kumar, A.; Banerjee, A.; Kumar, D.; Verma, S.K.; Sharma, A.K.; Bhatta, R.S.; Konwar, R. Tyrosine-Derived Novel Benzoxazine Active in a Rat Syngenic Mammary Tumor Model of Breast Cancer. J. Med. Chem. 2021, 64, 16293–16316. [Google Scholar] [CrossRef] [PubMed]
  23. Dickson, J.K.; Gungor, T.; Yang, W. 3-Aryl-hydroxybenzoxazines and 3,4-Dihydro-3-aryl-hydroxybenzoxazines as Selective Estrogen Receptor Beta Modulators. US7015219B2, 21 March 2006. [Google Scholar]
  24. Turner, J.V.; Agatonovic-Kustrin, S.; Glass, B.D. Molecular aspects of phytoestrogen selective binding at estrogen receptors. J. Pharm. Sci. 2007, 96, 1879–1885. [Google Scholar] [CrossRef] [PubMed]
  25. Saif, M.W.; Heaton, A.; Lilischkis, K.; Garner, J.; Brown, D.M. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). Cancer Chemother. Pharmacol. 2017, 79, 303–314. [Google Scholar] [CrossRef] [PubMed]
  26. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [PubMed]
  27. Hannah, R.; Beck, M.; Moravec, R.; Riss, T. CellTiter-Glo™ Luminescent cell viability assay: A sensitive and rapid method for determining cell viability. Promega Cell Notes 2001, 2, 11–13. [Google Scholar]
  28. Felicetti, T.; Cannalire, R.; Burali, M.S.; Massari, S.; Manfroni, G.; Barreca, M.L.; Tabarrini, O.; Schindler, B.D.; Sabatini, S.; Kaatz, G.W.; et al. Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues. ChemMedChem 2017, 12, 1293–1302. [Google Scholar] [CrossRef] [PubMed]
  29. Tian, Y.; Wang, X.; Xiao, Q.; Sun, C.; Yin, D. Synthesis of Dihydrobenzoheterocycles through Al(OTf)3-Mediated Cascade Cyclization and Ionic Hydrogenation. J. Org. Chem. 2014, 79, 9678–9685. [Google Scholar] [CrossRef] [PubMed]
  30. Wei, S.; Feng, X.; Du, H. A metal-free hydrogenation of 3-substituted 2H-1,4-benzoxazines. Org. Biomol. Chem. 2016, 14, 8026–8029. [Google Scholar] [CrossRef]
Molecules 29 00166 g001
Figure 1. Design of 4-aryl substituted 1,4-benzoxazines as anticancer agents.
Figure 1. Design of 4-aryl substituted 1,4-benzoxazines as anticancer agents.
Molecules 29 00166 g001
Molecules 29 00166 sch001
Scheme 1. Reagents and conditions: (a) K2CO3, acetone, rt, 6 h, N2, 72–83%; (b) H2, Pd/C, methanol, rt, 12 h, 50–95%; and (c) substituted bromobenzene, Pd2(dba)3, XPhos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 23–50%.
Scheme 1. Reagents and conditions: (a) K2CO3, acetone, rt, 6 h, N2, 72–83%; (b) H2, Pd/C, methanol, rt, 12 h, 50–95%; and (c) substituted bromobenzene, Pd2(dba)3, XPhos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 23–50%.
Molecules 29 00166 sch001
Molecules 29 00166 sch002
Scheme 2. Reagents and conditions: (a) K2CO3, acetone, rt, 6 h, N2, 62–90%; (b) H2, Pd/C, methanol, rt, 12 h, 50–60%; and (c) substituted bromobenzene, Pd2(dba)3, XPhos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 24–82%.
Scheme 2. Reagents and conditions: (a) K2CO3, acetone, rt, 6 h, N2, 62–90%; (b) H2, Pd/C, methanol, rt, 12 h, 50–60%; and (c) substituted bromobenzene, Pd2(dba)3, XPhos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 24–82%.
Molecules 29 00166 sch002
Molecules 29 00166 sch003
Scheme 3. Reagents and conditions: H2, Pd/C, methanol, rt, 12 h, 55–100%.
Scheme 3. Reagents and conditions: H2, Pd/C, methanol, rt, 12 h, 55–100%.
Molecules 29 00166 sch003
Molecules 29 00166 sch004
Scheme 4. Reagents and conditions: BBr3, DCM, rt, 8 h, N2, 40–100%.
Scheme 4. Reagents and conditions: BBr3, DCM, rt, 8 h, N2, 40–100%.
Molecules 29 00166 sch004
Molecules 29 00166 sch005
Scheme 5. Reagents and conditions: (a) 3-bromoquinoline, Pd2(dba)3, Xphos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 55%; (b) BBr3, DCM, rt, 8 h, N2, 89%.
Scheme 5. Reagents and conditions: (a) 3-bromoquinoline, Pd2(dba)3, Xphos, CsCO3, tert-butanol, toluene, 100 °C, 16 h, argon, 55%; (b) BBr3, DCM, rt, 8 h, N2, 89%.
Molecules 29 00166 sch005
Molecules 29 00166 g002
Figure 2. SAR conclusions of the designed 4-aryl-3,4-dihydro-2H-1,4-benzoxazine scaffold.
Figure 2. SAR conclusions of the designed 4-aryl-3,4-dihydro-2H-1,4-benzoxazine scaffold.
Molecules 29 00166 g002
Molecules 29 00166 g003
Figure 3. IC50 of molecule 14f in cancer cell lines.
Figure 3. IC50 of molecule 14f in cancer cell lines.
Molecules 29 00166 g003
Table 1. Cell growth inhibitory effect of the synthesised compounds and their cell growth inhibitory values in different cancer cell lines. Staurosporine (STS) was used as positive control.
Table 1. Cell growth inhibitory effect of the synthesised compounds and their cell growth inhibitory values in different cancer cell lines. Staurosporine (STS) was used as positive control.
CompoundsCell Growth Inhibition (%)
MIA PaCa-2MDA-MB-231PC-3
5a21 ± 4.59.1 ± 3.813 ± 0.5
5b30 ± 8.615 ± 0.90.8 ± 2.2
5c26 ± 3.944 ± 2.12.2 ± 0.9
5d21 ± 7.323 ± 1.30.2 ± 7.7
5e59 ± 6.353 ± 3.71.0 ± 2.8
10a−4.2 ± 4.4−7.2 ± 2.4−2.6 ± 0.6
10b17 ± 2.73.4 ± 1.97.2 ± 0.4
11a91 ± 1.142 ± 1111 ± 2.5
11b44 ± 4.024 ± 0.3−1.1 ± 1.6
11d48 ± 4.522 ± 5.6−0.6 ± 3.8
11e19 ± 3.214 ± 2.73.6 ± 2.2
11f33 ± 5.519 ± 9.8−1.3 ± 2.0
11g12 ± 1.828 ± 3.9−4.9 ± 1.1
1237 ± 6.424 ± 1.0−5.6 ± 0.3
13a37 ± 3.83.2 ± 3.0−5.2 ± 0.6
13b25 ± 12−1.8 ± 2.9−12 ± 6.9
13c59 ± 4.60.5 ± 0.125 ± 0.0
13d79 ± 1.520 ± 6.750 ± 6.2
13e52 ± 0.717 ± 1.5−18 ± 3.2
14a88 ± 0.862 ± 8.825 ± 6.5
14b57 ± 1111 ± 0.911 ± 3.3
14c75 ± 1552 ± 1.612 ± 1.8
14d94 ± 6.545 ± 0.91.6 ± 5.0
14e5.6 ± 3.9−4.8 ± 1.2−5.3 ± 1.4
14f99 ± 0.578 ± 0.498 ± 0.8
14g63 ± 7.014 ± 4.1−1.6 ± 5.9
15a72 ± 0.736 ± 0.912 ± 8.6
15b46 ± 3.728 ± 3.91.6 ± 0.5
IC50 (µM)
STS0.02210.00290.0591
Table 2. In silico predicted parameters of the compounds.
Table 2. In silico predicted parameters of the compounds.
CompoundsLipinski Rule
MWAccept HBDonor HBLog Po/wViolation
5a287.36104.040
5b332.35303.60
5c317.38204.030
5d362.38403.430
5e335.37304.340
10a269.3402.960
10b257.26403.280
11a347.41304.030
11b377.434040
11d375.46304.640
11e390.43404.080
11f365.4404.320
11g380.37503.730
12405.44504.140
13a302.37113.480
13b332.40 213.470
13c362.42313.470
13d360.45214.130
13e350.39313.790
14a303.35213.640
14b318.37223.080
14c319.35323.220
14d335.35432.810
14e334.37332.660
14f346.42223.710
14g337.34423.520
15a396.48304.940
15b386.42404.610
Description: Lipinski rule—Number of violations of Lipinski’s rule of five. The rules are as follows: MW < 500, accept HB ≤ 10, donor HB < 5, Log Po/w < 5 and maximum 4 violations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Fu, X.; Wenholz, D.; Chan, D.S.H.; Black, D.S.; Kumar, N. Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines. Molecules 2024, 29, 166. https://doi.org/10.3390/molecules29010166

AMA Style

Fu X, Wenholz D, Chan DSH, Black DS, Kumar N. Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines. Molecules. 2024; 29(1):166. https://doi.org/10.3390/molecules29010166

Chicago/Turabian Style

Fu, Xiaoming, Daniel Wenholz, Daniel S. H. Chan, David StC. Black, and Naresh Kumar. 2024. "Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines" Molecules 29, no. 1: 166. https://doi.org/10.3390/molecules29010166

APA Style

Fu, X., Wenholz, D., Chan, D. S. H., Black, D. S., & Kumar, N. (2024). Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines. Molecules, 29(1), 166. https://doi.org/10.3390/molecules29010166

Article Metrics

Back to TopTop